Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Biocytogen (02315.HK) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies.

Using its proprietary RenMab^TM/RenLite^®/RenNano^®mice platforms for fully human monoclonal, bispecific antibody and nanobody development, Biocytogen has integrated itsin vivodrug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process.

Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMice^TMlicensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany.

Primary Activity

Material Manufacturer